El próximo viernes 16 de abril, a las 12 h, tendremos el placer de contar con la participación de los Dres. Elena Castro (IBIMA, Málaga) y David Olmos (CNIO, Madrid) que nos impartirán la conferencia titulada: Deciphering the clinical and biological consequences of deficient DNA repair in prostate cancer. La Dres. Castro y Olmos han sido invitados por el profesor José Lozano (Dpto. Biología Molecular y Bioquímica UMA). Debido a la situación de emergencia sanitaria por COVID-19, la conferencia tendrá lugar online a través de la plataforma Google Meet. Podréis acceder mediante el siguiente enlace: https://meet.google.com/jfh-mopr-zsp
Publicaciones recientes:
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Eur J Cancer. 2021 Apr; 147:74-83.
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D. Br J Cancer. 2021 Feb;124(3):552-563.
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. Merseburger AS, Waldron N, Ribal MJ, Heidenreich A, Perner S, Fizazi K, Sternberg CN, Mateo J, Wirth MP, Castro E, Olmos D, Petrylak DP, Chowdhury S. Eur Urol. 2021 Apr;79(4):519-529.
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Ruiz de Porras V, Wang XC, Palomero L, Marin-Aguilera M, Solé-Blanch C, Indacochea A, Jimenez N, Bystrup S, Bakht M, Conteduca V, Piulats JM, Buisan O, Suarez JF, Pardo JC, Castro E, Olmos D, Beltran H, Mellado B, Martinez-Balibrea E, Font A, Aytes A. Eur Urol. 2020 Nov 2:S0302-2838(20)30778-8.
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cattrini C, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, Messina C, Castro E, Olmos D, Boccardo F. Cancers (Basel) 2020 Oct 3;12(10):2855.
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. J Oncol. 2020 Sep 7;2020:4986365.
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodríguez-Vida A, Lainez N, Villatoro R, Llácer C, Cattrini C, Hernández A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, López-Campos F, Gonzalez B, Méndez-Vidal MJ, Medina A, Piulats JM, Olmos D; PROREPAIR-B Study Investigators. Eur Urol. 2020 Jun;77(6):763-766.
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D. Cancers (Basel). 2019 Sep 12;11(9):1355.
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S, Caffo O, Zivi A, Pezaro CJ, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez MI, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS. Eur Urol Oncol. 2020 Apr;3(2):176-182.
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E. Eur Urol Oncol. 2019 Jul 13:S2588-9311(19)30100-2.
